Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1

 

 

 

Taigang Liang | Drug Design | Best Researcher Award

Prof. Taigang Liang | Drug Design | Best Researcher Award

Professor at School of Pharmacy/Shanxi Medical University, China.

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Professional Profiles:

Education

Prof. Tai Gang Liang, a distinguished scientist at Shanxi Medical University’s School of Pharmacy, has a robust educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (PhD) in 2011, Master of Science (MS) in 2003, and Bachelor of Science (BS) in 2000, all from Shanxi Medical University. His extensive expertise spans drug synthesis, drug action mechanisms, computer-aided drug design, and the industrialization of traditional Chinese medicine (TCM). Prof. Liang’s research is recognized for its contributions to both the development of novel drug compounds and innovative drug design methodologies. His academic journey reflects a deep commitment to advancing pharmaceutical sciences and addressing global health challenges through cutting-edge research.

Professional Experience

Prof. Tai Gang Liang is a distinguished scientist at the School of Pharmacy, Shanxi Medical University, with extensive expertise in drug synthesis, drug action mechanisms, and computer-aided drug design. His research also focuses on the industrialization of traditional Chinese medicine (TCM). Over his career, Prof. Liang has received several prestigious awards, including being named a Shanxi Province Outstanding Young Scholar and a member of the Shanxi Province “131 Leading Talent Engineering.” He also earned the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition. His work has made significant contributions to advancing pharmaceutical sciences and TCM research, reflecting his dedication to innovation and excellence in the field.

 Research Interest

Prof. Tai Gang Liang’s research interests encompass a broad spectrum within pharmaceutical sciences. His primary focus includes drug synthesis and drug action mechanisms, where he aims to develop novel therapeutic agents and understand their biological effects. He is also deeply involved in computer-aided drug design, utilizing computational tools to optimize drug development processes. Additionally, Prof. Liang investigates the industrialization of traditional Chinese medicine (TCM), striving to integrate traditional practices with modern scientific techniques to enhance the efficacy and application of TCM therapies. His research aims to bridge the gap between traditional and modern medicinal approaches, advancing both fields through innovative solutions and interdisciplinary collaboration.

Award and Honors

Prof. Tai Gang Liang has received several notable awards and honors in recognition of his contributions to the field of pharmaceutical sciences. He was named a Shanxi Province Outstanding Young Scholar, highlighting his exceptional achievements and potential in his research domain. He is also a member of the Shanxi Province “131 Leading Talent Engineering”, an accolade given to influential professionals in the province. Additionally, Prof. Liang was awarded the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition, reflecting his innovative approach and entrepreneurial spirit in scientific endeavors. These accolades underscore his dedication and significant impact in drug development and traditional Chinese medicine. 🏆🌟

 Research Skills

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Publications
  1. Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis
    • Authors: D Cui, T Liang, L Sun, L Meng, C Yang, L Wang, T Liang, Q Li
    • Year: 2018
    • Citations: 112
  2. Comparison of the Phenolic Content and Antioxidant Activities of Apocynum venetum L. (Luo-Bu-Ma) and Two of Its Alternative Species
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 107
  3. Selenium nanoparticles fabricated in laminarin polysaccharides solutions exert their cytotoxicities in HepG2 cells by inhibiting autophagy and promoting apoptosis
    • Authors: D Cui, J Ma, T Liang, L Sun, L Meng, T Liang, Q Li
    • Year: 2019
    • Citations: 93
  4. Synthesis, characterization and antitumor properties of selenium nanoparticles coupling with ferulic acid
    • Authors: D Cui, C Yan, J Miao, X Zhang, J Chen, L Sun, L Meng, T Liang, Q Li
    • Year: 2018
    • Citations: 78
  5. Chemopreventive Effects of Peucedanum praeruptorum DUNN and Its Major Constituents on SGC7901 Gastric Cancer Cells
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 51
  6. Farrerol Directly Targets GSK‐3β to Activate Nrf2‐ARE Pathway and Protect EA.hy926 Cells against Oxidative Stress‐Induced Injuries
    • Authors: C Yan, X Zhang, J Miao, H Yuan, E Liu, T Liang, Q Li
    • Year: 2020
    • Citations: 37
  7. Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway
    • Authors: E Liu, T Liang, X Wang, S Ban, L Han, Q Li
    • Year: 2015
    • Citations: 35
  8. Diorganotin (IV) complexes with 4-nitro-N-phthaloyl-glycine: Synthesis, characterization, antitumor activity and DNA-binding studies
    • Authors: C Yan, J Zhang, T Liang, Q Li
    • Year: 2015
    • Citations: 35
  9. Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs
    • Authors: X Qin, X Hou, M Zhang, T Liang, J Zhi, L Han, Q Li
    • Year: 2014
    • Citations: 31
  10. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest
    • Authors: E Liu, J Li, S Shi, X Wang, T Liang, B Wu, Q Li
    • Year: 2016
    • Citations: 26